You are here: Home » Companies » News
Business Standard

Panacea Biotec to make 100 mn doses of Sputnik V for global markets

More players like Serum Institute expected to join the fray to make Sputnik V

Coronavirus | Panacea Biotec

Sohini Das  |  Mumbai 

A paramedic holds a pack of used and unused vials of Russia's Sputnik V coronavirus disease vaccine at a private hospital in Karachi (Photo: Reuters)

As India emerges as a major manufacturing hub for the Russian vaccine Sputnik V, the latest firm to partner with Russian Direct Investment Fund (RDIF) to make the Sputnik V vaccine in India is that will make 100 million doses of the vaccine here annually for the global market.

With this the total manufacturing capacity of Sputnik V in India becomes 852 million doses annually from partners including Stelis Pharma (Strides arm), Hetero, Gland Pharma, Virchow Group. More players are likely to sign manufacturing agreements with RDIF soon, claimed sources.

Apart from Panacea Biotec, even Serum Institute of India is likely to sign a contract manufacturing agreement with RDIF, claimed sources in the know. Serum Institute, however, did not comment on the matter.

ALSO READ: Coronavirus LIVE: Maharashtra records 47,288 new cases, 155 deaths

Hyderabad based Dr Reddy’s Laboratories is going to distribute the vaccine in India and DRL and RDIF have lined up around 250 million doses for India. The remaining production in India will be exported.

Sputnik V has been registered in 59 countries globally with total population of over 1.5 billion people. Efficacy of Sputnik V is 91.6 per cent.

Rajesh Jain, Managing Director of Panacea Biotec, said that it will make Sputnik V for global markets at facilities complying with strict GMP standards and prequalified by WHO.

The vaccine is yet to get nod from India’s drugs regulator for use in India. DRL is expected to present more data on safety, immune response and logistics plan before the subject expert panel soon.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, April 05 2021. 21:10 IST